Preclinical Complete: What Our Murine Model Data Actually Shows
42% faster closure by Day 7. ~90% closure in a diabetic model by Day 10. Zero adverse events across all tox cohorts. A breakdown of the numbers.
The Cold-Chain Trap: Why Biologics Are Failing the World’s Most Vulnerable Patients
94% of DFU patients in low-resource settings never receive advanced therapy. Refrigeration requirements are a silent policy failure — one ZegeneX was built to solve.
How Zegen-X5 Rewires the Wound-Healing Cascade — Without Feedback Inhibition
Most growth-factor biologics hit a ceiling: the body downregulates its own receptors in response to exogenous PDGF. Our small-molecule approach sidesteps that problem entirely by targeting upstream regulators — driving keratinocyte proliferation and angiogenesis through a mechanism no approved therapy has exploited before.
